CARTER-WALLACE TAKING $36.6 MIL. IN FELBATOL CHARGES: NET SALES UP 12% TO $168.1 MIL.; CHIRON BETASERON SALES ARE $61 MIL. YEAR TO DATE; EQUITY INVESTMENT IN WORKS
Executive Summary
Carter-Wallace is taking a one-time pre-tax charge of $36.6 mil. in the second quarter (ended Sept. 30) related to its anticonvulsant Felbatol for inventory write-offs, purchase commitments and anticipated product returns, C-W reported Nov. 10.